Zacks: Analysts Expect Fluidigm Co. (NASDAQ:FLDM) Will Announce Earnings of -$0.11 Per Share

Wall Street brokerages expect Fluidigm Co. (NASDAQ:FLDM) to report earnings per share of ($0.11) for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Fluidigm’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.11). Fluidigm posted earnings of ($0.06) per share in the same quarter last year, which would suggest a negative year over year growth rate of 83.3%. The business is expected to report its next earnings results on Thursday, February 6th.

On average, analysts expect that Fluidigm will report full-year earnings of ($0.44) per share for the current year, with EPS estimates ranging from ($0.44) to ($0.43). For the next financial year, analysts forecast that the company will report earnings of ($0.36) per share, with EPS estimates ranging from ($0.36) to ($0.35). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Fluidigm.

Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.19) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.01. The company had revenue of $26.50 million for the quarter, compared to the consensus estimate of $28.74 million. Fluidigm had a negative net margin of 57.10% and a negative return on equity of 25.11%. The firm’s revenue for the quarter was down 8.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.13) earnings per share.

Several research analysts have weighed in on FLDM shares. Janney Montgomery Scott downgraded shares of Fluidigm from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 6th. Zacks Investment Research upgraded shares of Fluidigm from a “sell” rating to a “hold” rating in a research report on Saturday, January 4th. ValuEngine upgraded shares of Fluidigm from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. UBS Group upgraded shares of Fluidigm from a “neutral” rating to a “buy” rating and decreased their price target for the stock from $14.00 to $7.00 in a research report on Friday, October 18th. Finally, BidaskClub upgraded shares of Fluidigm from a “sell” rating to a “hold” rating in a research report on Saturday, November 2nd. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Fluidigm has a consensus rating of “Buy” and a consensus price target of $10.81.

Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC grew its stake in shares of Fluidigm by 21,055.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,135 shares of the medical research company’s stock worth $29,000 after buying an additional 6,106 shares in the last quarter. Metropolitan Life Insurance Co NY purchased a new position in shares of Fluidigm in the 1st quarter worth $151,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Fluidigm in the 2nd quarter worth $154,000. Bailard Inc. purchased a new position in shares of Fluidigm in the 3rd quarter worth $59,000. Finally, Prudential Financial Inc. grew its stake in shares of Fluidigm by 55.6% in the 2nd quarter. Prudential Financial Inc. now owns 15,950 shares of the medical research company’s stock worth $197,000 after buying an additional 5,700 shares in the last quarter. 90.99% of the stock is owned by institutional investors and hedge funds.

Shares of Fluidigm stock opened at $3.46 on Thursday. The company has a market cap of $240.71 million, a price-to-earnings ratio of -4.33 and a beta of 2.21. The company’s 50 day moving average is $2.99 and its 200 day moving average is $5.93. Fluidigm has a twelve month low of $2.12 and a twelve month high of $14.90. The company has a quick ratio of 2.44, a current ratio of 2.89 and a debt-to-equity ratio of 0.33.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Featured Article: What is a Real Estate Investment Trust (REIT)?

Get a free copy of the Zacks research report on Fluidigm (FLDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit